GGrantIndex
← Leaderboards

Raphael J Landovitz

University Of California Los Angeles

$12,045,588
Attributed
$22,818,970
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.8M · FY200925
$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,573,780 · 6

By mechanism

UM1$21,546,764 · 1
P30$2,211,500 · 2
K23$789,985 · 1
M01$25,531 · 2

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Aids Prevention

Research focus

Aids PreventionMentorsComorbidityPrevention StrategyHiv InfectionsDesignCaliforniaCommunitiesPreventionLos AngelesEnrollmentResearch PersonnelInfectionSuccessMultidisciplinaryMental HealthNovel StrategiesCollaborationsEpidemicAcquired Immunodeficiency SyndromePersonsMen Who Have Sex With MenMentorshipArea

Grant awards (15)

UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,585,709
UM1 · FY2025 · AI · contact PI
Center for HIV Identification, Prevention and Treatment Services$1,499,315
P30 · FY2025 · MH · contact PI
Administrative Core$456,690
P30 · FY2025 · MH · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,954,316
UM1 · FY2024 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,794,297
UM1 · FY2023 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$4,384,228
UM1 · FY2022 · AI
Financially incentivizing HIV prevention among high-incidence populations in LA County: Preparing for implementation$255,495
P30 · FY2022 · MH
UCLA AIDS Prevention and Treatment Clinical Trials Unit$5,828,214
UM1 · FY2021 · AI
Biomedical Prevention for HIV in High-risk Populations with Comorbidities$157,397
K23 · FY2013 · DA · contact PI
Biomedical Prevention for HIV in High-risk Populations with Comorbidities$157,397
K23 · FY2012 · DA · contact PI
Biomedical Prevention for HIV in High-risk Populations with Comorbidities$157,397
K23 · FY2011 · DA · contact PI
Biomedical Prevention for HIV in High-risk Populations with Comorbidities$157,397
K23 · FY2010 · DA · contact PI
THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS (OPTIONS) TRIAL: A RANDOMIZ$7,911
M01 · FY2010 · RR · contact PI
Biomedical Prevention for HIV in High-risk Populations with Comorbidities$160,397
K23 · FY2009 · DA · contact PI
THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS (OPTIONS) TRIAL: HIV$17,620
M01 · FY2009 · RR · contact PI